ChristopherH.SorliMD

Diabetes, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology, Thyroid

Physician

Dr. Sorli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of MinnesotaFellowship, Endocrinology, Diabetes, and Metabolism, 1994 - 1998
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1991 - 1994
University of Massachusetts Medical SchoolClass of 1991

Regional Top Doctor Castle Connolly, 2014
Diabetes Recognition Program National Committee for Quality Assurance, 2010-2013

PubMed

5 citations
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline.
Richard E Pratley, Stephan Jacob, Seungjae Baek, Michael E Trautmann, Marcus Hompesch
BMJ Open Diabetes Research & Care. 2022-01-01
8 citations
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized p...
Marcus Hompesch, Jahoon Kang, Oakpil Han, Michael E. Trautmann, Christopher H. Sorli
BMJ Open Diabetes Research & Care. 2021-06-01
18 citations
Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.
Kun-Ho Yoon, Jahoon Kang, Se Chang Kwon, Michael E. Trautmann, Marcus Hompesch
Diabetes, Obesity & Metabolism. 2020-08-01

Acerus Reports Fiscal Third Quarter Financial ResultsNovember 3rd, 2020
Semaglutide Shows Benefits for Type 2sFebruary 18th, 2017
Elderly Diabetics Have Fewer Bouts of Hypoglycemia at Night with New InsulinJune 25th, 2012